The authors used designed binders that recognise cell-surface receptors to redirect AAV capsids, the viral shells used to carry genes, towards targeted gene delivery.

The paper

The paper's details are OpenAlex's; the citation count is OpenAlex's, 19 Oct 2026. The line on the paper is machine-written, as noted under Why it matters.

Why it matters

Written by Claude (claude-sonnet-5-5) on 19 Oct 2026 from the paper's abstract (as the publisher's record at Crossref publishes it) and its OpenAlex record. Machine-written context to help a reader: it is not evidence, it moves no number, and it may be wrong. The quoted sentence is the claim; where it stands is computed from the record. If it misreads the paper, tell the stewards.

The story so far

1. 1

   What the authors did

   The authors built a computational design pipeline built on AlphaFold2 weights and tested its binders experimentally against targets including cell-surface receptors, allergens, designed proteins and Cas9. The abstract does not give further detail on the AAV experiments.

   Machine-written from the paper's abstract, as noted under Why it matters.

2. 2

   What they found

   • BindCraft designs de novo protein binders with reported experimental success rates of 10-100%, with nanomolar affinity and no need for high-throughput screening or experimental optimisation.
   • Binders were designed against diverse challenging targets, including cell-surface receptors, common allergens, de novo designed proteins and multi-domain nucleases such as CRISPR-Cas9.
   • Designed binders reduced IgE binding to birch allergen in patient-derived samples, modulated Cas9 gene editing activity and reduced the cytotoxicity of a foodborne bacterial enterotoxin.

   Machine-written from the paper's abstract, as noted under Why it matters.

3. 3

   What has been checked on Ecdysis

   Exuvia registered the claim on 19 October 2026, with a test written from the paper. No check has been filed yet.

What would check it

How far it has been checked

1. 1
   The object itself, checked againverification · not yet

   Not yet: re-run the paper's analysis on its own data, where the authors have published it.

2. 2
   New instances of the constructionreproduction · not yet

   Not yet: the same construction run afresh.

3. 3
   The designrobustness tests and arguments · not yet

   Nothing yet: change the method or the data and see whether it holds (a robustness test), or argue that the method does not test what the claim says.

How sure is the record?

Share this finding

Ready-made posts, written from the record. You post them yourself, from your own account; nothing is ever posted for anyone.

Click a post's text to select all of it. Both posts give the claim's standing on the record, and the longer one says what the checks show and what they do not; the wording changes when the record does. The longer post quotes the paper first, then gives the machine-written headline, marked as such; edit it as you like. To cite the claim, see Cite this claim.

What would prove it wrong

Refuted if no BindCraft-designed cell surface receptor‑specific binder demonstrates successful redirection of an AAV capsid to a target cell line in a quantitative transduction assay with ≥10% increase over control.

The test as Exuvia registered it on 19 Oct 2026, written from the paper's words.

The wider literature

Other claims from the same paper

• uncheckedBindCraft uses AlphaFold2's weights to design protein binders with nanomolar affinity, without large-scale screening or optimisation, even with no known binding site.“BindCraft leverages the weights of AlphaFold2 1 to generate binders with nanomolar affinity without the need for high-throughput screening or experimental optimization, even in the absence of known b…”
• uncheckedWe successfully designed binders against a diverse set of challenging targets, including cell-surface receptors, common allergens, de novo designed proteins, and multi-domain nucleases, such as CRISPR-Cas9.

Headlines are machine-written from the paper's abstract, or from the quote and the paper's title where no abstract is open; each claim's own words are quoted beneath its headline.